vs

Side-by-side financial comparison of Broadway Financial Corp (BYFC) and IRIDEX CORP (IRIX). Click either name above to swap in a different company.

IRIDEX CORP is the larger business by last-quarter revenue ($14.7M vs $9.4M, roughly 1.6× Broadway Financial Corp). On growth, Broadway Financial Corp posted the faster year-over-year revenue change (10.1% vs -69.7%). Over the past eight quarters, IRIDEX CORP's revenue compounded faster (11.9% CAGR vs 9.7%).

Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

BYFC vs IRIX — Head-to-Head

Bigger by revenue
IRIX
IRIX
1.6× larger
IRIX
$14.7M
$9.4M
BYFC
Growing faster (revenue YoY)
BYFC
BYFC
+79.8% gap
BYFC
10.1%
-69.7%
IRIX
Faster 2-yr revenue CAGR
IRIX
IRIX
Annualised
IRIX
11.9%
9.7%
BYFC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BYFC
BYFC
IRIX
IRIX
Revenue
$9.4M
$14.7M
Net Profit
$1.0M
Gross Margin
37.2%
Operating Margin
Net Margin
1934.0%
Revenue YoY
10.1%
-69.7%
Net Profit YoY
-21.8%
EPS (diluted)
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BYFC
BYFC
IRIX
IRIX
Q4 25
$9.4M
$14.7M
Q3 25
$9.0M
$12.5M
Q2 25
$8.1M
$13.6M
Q1 25
$8.3M
$11.9M
Q4 24
$8.6M
$12.7M
Q3 24
$8.7M
$11.6M
Q2 24
$8.2M
$12.6M
Q1 24
$7.8M
$11.8M
Net Profit
BYFC
BYFC
IRIX
IRIX
Q4 25
$1.0M
Q3 25
$-23.9M
$-1.6M
Q2 25
$752.0K
$-994.0K
Q1 25
$-2.7M
$-1.7M
Q4 24
$1.3M
$-834.0K
Q3 24
$516.0K
$-1.9M
Q2 24
$256.0K
$-2.7M
Q1 24
$-154.0K
$-3.5M
Gross Margin
BYFC
BYFC
IRIX
IRIX
Q4 25
37.2%
Q3 25
32.1%
Q2 25
34.5%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
Q1 24
37.9%
Operating Margin
BYFC
BYFC
IRIX
IRIX
Q4 25
Q3 25
-256.2%
-11.3%
Q2 25
12.8%
-6.9%
Q1 25
-45.3%
-1.7%
Q4 24
21.7%
-3.9%
Q3 24
8.5%
-16.1%
Q2 24
4.8%
-20.9%
Q1 24
-2.9%
-28.0%
Net Margin
BYFC
BYFC
IRIX
IRIX
Q4 25
1934.0%
Q3 25
-264.2%
-12.6%
Q2 25
9.3%
-7.3%
Q1 25
-32.3%
-14.2%
Q4 24
15.3%
-6.6%
Q3 24
5.9%
-16.7%
Q2 24
3.1%
-21.2%
Q1 24
-2.0%
-29.5%
EPS (diluted)
BYFC
BYFC
IRIX
IRIX
Q4 25
$0.02
Q3 25
$-2.86
$-0.09
Q2 25
$0.00
$-0.06
Q1 25
$-0.39
$-0.10
Q4 24
$0.07
$-0.05
Q3 24
$-0.03
$-0.12
Q2 24
$0.02
$-0.16
Q1 24
$-0.02
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BYFC
BYFC
IRIX
IRIX
Cash + ST InvestmentsLiquidity on hand
$10.5M
$6.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$262.8M
Total Assets
$1.3B
$29.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BYFC
BYFC
IRIX
IRIX
Q4 25
$10.5M
$6.0M
Q3 25
$19.7M
$5.6M
Q2 25
$29.5M
$6.8M
Q1 25
$15.8M
$7.2M
Q4 24
$61.4M
$2.4M
Q3 24
$97.1M
$3.9M
Q2 24
$89.8M
$4.1M
Q1 24
$67.1M
$5.4M
Total Debt
BYFC
BYFC
IRIX
IRIX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
Q3 24
$1.4M
Q2 24
Q1 24
Stockholders' Equity
BYFC
BYFC
IRIX
IRIX
Q4 25
$262.8M
Q3 25
$261.7M
$4.7M
Q2 25
$284.7M
$6.1M
Q1 25
$283.6M
$852.0K
Q4 24
$285.0M
$2.1M
Q3 24
$286.2M
$2.6M
Q2 24
$282.1M
$4.2M
Q1 24
$281.1M
$6.5M
Total Assets
BYFC
BYFC
IRIX
IRIX
Q4 25
$1.3B
$29.2M
Q3 25
$1.3B
$28.4M
Q2 25
$1.2B
$31.6M
Q1 25
$1.3B
$34.2M
Q4 24
$1.3B
$29.1M
Q3 24
$1.4B
$30.2M
Q2 24
$1.4B
$31.2M
Q1 24
$1.4B
$34.1M
Debt / Equity
BYFC
BYFC
IRIX
IRIX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
Q3 24
0.53×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BYFC
BYFC
IRIX
IRIX
Operating Cash FlowLast quarter
$230.0K
Free Cash FlowOCF − Capex
$-13.0K
FCF MarginFCF / Revenue
-0.1%
Capex IntensityCapex / Revenue
2.6%
Cash ConversionOCF / Net Profit
0.22×
TTM Free Cash FlowTrailing 4 quarters
$2.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BYFC
BYFC
IRIX
IRIX
Q4 25
$230.0K
Q3 25
$3.8M
$-1.2M
Q2 25
$3.0M
$-397.0K
Q1 25
$-4.3M
$-1.1M
Q4 24
$1.4M
$-1.2M
Q3 24
$6.1M
$-3.1M
Q2 24
$9.8M
$-1.3M
Q1 24
$-11.7M
$-1.6M
Free Cash Flow
BYFC
BYFC
IRIX
IRIX
Q4 25
$-13.0K
Q3 25
$3.7M
$-1.2M
Q2 25
$3.0M
$-410.0K
Q1 25
$-4.4M
$-1.2M
Q4 24
$1.3M
$-1.2M
Q3 24
$6.1M
$-3.1M
Q2 24
$9.7M
Q1 24
$-11.7M
$-1.7M
FCF Margin
BYFC
BYFC
IRIX
IRIX
Q4 25
-0.1%
Q3 25
41.1%
-9.4%
Q2 25
37.0%
-3.0%
Q1 25
-52.4%
-9.8%
Q4 24
14.7%
-9.8%
Q3 24
69.6%
-26.5%
Q2 24
118.9%
Q1 24
-149.7%
-14.0%
Capex Intensity
BYFC
BYFC
IRIX
IRIX
Q4 25
2.6%
Q3 25
1.2%
0.1%
Q2 25
0.2%
0.1%
Q1 25
0.2%
0.1%
Q4 24
1.6%
0.1%
Q3 24
0.3%
0.0%
Q2 24
0.5%
0.0%
Q1 24
0.7%
0.0%
Cash Conversion
BYFC
BYFC
IRIX
IRIX
Q4 25
0.22×
Q3 25
Q2 25
4.00×
Q1 25
Q4 24
1.06×
Q3 24
11.85×
Q2 24
38.21×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons